Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6091 to 6105 of 8314 results

  1. More research is needed on using the following digital weight-management technologies:

    Recommendation ID HTE14 Question More research is needed on using the following digital weight-management technologies: Any explanatory

    Research recommendation
    Published
    11 January 2024

  2. More research is recommended on UroShield for preventing catheter associated urinary tract infections (UTIs). It has potential to provide significant patient and healthcare system benefits but uncertainties in the evidence need to be addressed. Research should be comparative, and it should address uncertainties about the effectiveness of UroShield in preventing catheter-associated UTIs and other catheter-related complaints such as blockages. Find out more in the further research section of this guidance.

    Recommendation ID MTG69/01 Question More research is recommended on UroShield for preventing catheter associated urinary tract infections

    Research recommendation
    Published
    8 April 2022

  3. More research or data collection is recommended on Sleepio for people who are eligible for face-to-face cognitive behavioural therapy for insomnia (CBT-I) in primary care. This is because there is limited clinical evidence to show how effective Sleepio is compared with face-to-face CBT-I. A real-world study is suggested to compare the effectiveness of Sleepio with face-to-face CBT-I.

    Recommendation ID MTG70/01 Question More research or data collection is recommended on Sleepio for people who are eligible for face-to-face

    Research recommendation
    Published
    31 May 2022

  4. More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.

    Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee

    Research recommendation
    Published
    9 June 2015

  5. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    Recommendation ID TA293/2 Question NICE recommends research generating and analysing observational data including, but not limited to,

    Research recommendation
    Published
    9 June 2015

  6. [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.

    Recommendation ID TA161/2 Question [NICE] recommends research into the long-term effects of bisphosphonates on bone quality, given the

    Research recommendation
    Published
    9 June 2015

  7. NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all patients having whole lymph node analysis by the RD-100i OSNA system should be submitted to this registry. These data should be integrated with data from other registries for breast cancer where appropriate.

    Recommendation ID DG8/1 Question NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system

    Research recommendation
    Published
    9 June 2015

  8. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    Recommendation ID TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  10. NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital episode, with a view to informing the cost-effectiveness modelling and reducing uncertainty.

    Recommendation ID DG13/4 Question NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital

    Research recommendation
    Published
    9 June 2015

  11. NICE recommends that health economic models are developed to capture the impact of interventions on short-term outcomes such as hypoglycaemia. In addition, the feasibility of incorporating more recently developed risk prediction models for cardiovascular disease such as QRisk2 and observational data from registries such as the Swedish National Diabetes Register into health economic models for type 1 diabetes should be explored.

    Recommendation ID DG21/3 Question NICE recommends that health economic models are developed to capture the impact of interventions on short-term

    Research recommendation
    Published
    11 April 2016

  12. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin

    Research recommendation
    Published
    9 June 2015

  13. NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.

    Recommendation ID DG16/2 Question NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic

    Research recommendation
    Published
    9 June 2015

  14. NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR-TK mutation test methods and should link to patient outcomes.

    Recommendation ID DG9/1 Question NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase

    Research recommendation
    Published
    9 June 2015

  15. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015